Autologous Redirected RNA Meso-CIR T Cells

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Abramson Cancer Center of the University of Pennsylvania
Sponsor:
Information provided by:
Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01355965
First received: May 17, 2011
Last updated: September 16, 2013
Last verified: September 2013

May 17, 2011
September 16, 2013
May 2011
May 2014   (final data collection date for primary outcome measure)
Adverse Events [ Time Frame: Until week 4 ] [ Designated as safety issue: Yes ]
Occurence of study related adverse events greater than to equal to Grade 3 events that are possibly, likely or definitely related to study treatment.
Same as current
Complete list of historical versions of study NCT01355965 on ClinicalTrials.gov Archive Site
Clinical response Rate [ Time Frame: through 6 months post dosing ] [ Designated as safety issue: Yes ]
Effect of CIR T cell infusion on systemic adaptive and innate immunity
Same as current
Not Provided
Not Provided
 
Autologous Redirected RNA Meso-CIR T Cells
Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients With Progressive Malignant Pleural Mesothelioma

To determine the safety and manufacturing feasibility of IV autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin messenger RNA (mRNA) expressing a single chain antibody variable fragment linked to the intracellular CD 3 zeta T cell receptor domain and the 4-1BB costimulatory domain.

The purpose of this study is to test the safety of infusing the study product CIR T cells. These T cells are made using T cells obtained through apheresis and introducing the T cells to a temporary gene which will cause them to start making a new type of antibody that will attach mesothelin (this antibody is found on the surface of the cancer cells). In theory, once the modified T cells attach to mesothelin, the cells will be activated to stimulate the subject's own immune system to attack the mesothelin cells. This type of modified cell is called a T cell transduced transfected with chimeric anti-mesothelin immunoreceptor. Subjects will be enrolled serially with all subjects receiving 1xe8 to 1x1e9 modified CIR T cells every other day for 3 infusions. Each patient will be observed for 9 days for toxicity assessment prior to receiving a second cycle of modified CIR T cells every other day for 3 infusions. The preceding subject must have completed the two-cycle regimen and been observed for toxicity through day 21 before the next subject can be enrolled.

Interventional
Phase 1
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Malignant Pleural Mesothelioma
Biological: Autologous T cells
  • Experimental: Cohort 1 - One dose of cells
    Intervention: Biological: Autologous T cells
  • Experimental: Cohort 2 - three doses of cells
    Intervention: Biological: Autologous T cells
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
6
May 2014
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must have histologically confirmed MPM (epithelial or biphasic).
  • Subjects must have completed standard first line therapy with a platinum-based double regimen and had PD or they must have chosen not to pursue primary standard of care therapy.
  • ECOG performance status 0 to 1.
  • Age greater than 18 years
  • Life expectancy > 4 months
  • At least 2 weeks since prior and no other concurrent chemotherapy, radiotherapy, or immunotherapy (e.g., interferons, tumor necrosis factor, interleukins, or monoclonal antibodies). In addition, the patient must have fully recovered from any adverse events related to these agents.
  • More than 4 weeks since prior and no other concurrent investigational agents.
  • Subjects must have measurable disease as defined by accepted MPM measurement techniques (modified RECIST criteria).
  • Blood coagulation parameters: PT such that international normalized ratio (INR) is < 1.5 (or an in-range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus) and a PTT < 1.2 times the upper limit of normal.
  • Subjects must have adequate venous peripheral access for apheresis. Patients must also have adequate venous access for subsequent modified CIR T-cell administration which can be done through a central venous access (e.g. port of systemic chemotherapy).
  • Short-term therapy for acute conditions not specifically related to MPM is allowed if such therapy does not include any immune modulating agents.
  • Male and Female subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device , abstinence) during the study and for 3 months following the last dose of the study cell infusion.
  • Subject must understand and sign the study-specific informed consent .
  • Satisfactory organ and bone marrow function as defined by :

Absolute neutrophil count > 1,000/µl Platelets > 100,000/µl Hematocrit > 30 % AST(SGOT)/ALT(SGPT) < 3x the institutional normal upper limit Bilirubin < 2.0 mg/dL unless secondary to malignant bile duct obstruction Creatinine < 1.5x the institutional normal upper limit

Exclusion Criteria:

  • Previously treated with any investigation therapy within 1 month prior to screening.
  • Sacromatoid MPM histology which does not express mesothelin
  • Prior invasive malignancies unless surgically and medically cured without evidence of recurrent disease for 5 years with the exception of non-melanoma skin cancer, prostate cancer with PSA level < 1.0.
  • Prior hematologic malignancy with bone marrow transplantation or immune modifying therapy within the past 4 weeks with the exception of thyroid replacement.
  • Use of immunosuppressive drugs with 4 weeks prior to study entry, or anticipated use of immunosuppressive agents.
  • Any clinically -significant pericardial effusion, CHF (NY Heart Association Grade II-IV ), or cardiovascular condition.
  • Any clinically -significant pleural effusion or ascites that cannot be drained with standard approaches or with pre-enrollment in dwelling drainage device placement.
  • Forced vital capacity < 50% predicted, DLCO < 40% predicted.
  • Underlying lung disease requiring supplemental oxygen therapy.
  • Have a recognized immunodeficiency disease including cellular immunodeficiency, hypogammaglobulinemia, or dysgammaglobulinemia; patients who have acquired hereditary, congenital immunodeficiency.
  • Viral infections: HIV, HCV, HBV.
  • Pregnant women are excluded from this study because autologous transduced T cells, breastfeeding should be discontinued if the mother is treated.
  • Feasibility assessment during screening demonstrates < 30% transfection of target lymphocytes, or < 5-fold expansion in modified CIR T-cells in response to CD3/CD28 costimulation.
Both
18 Years and older
No
Contact: Andrew R Haas, MD, PhD 855-216-0098 PennCancerTrials@emergingmed.com
United States
 
NCT01355965
UPCC 17510
Yes
Andrew R. Haas, MD, PhD, Abramson Cancer Center of the University of Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Not Provided
Not Provided
Abramson Cancer Center of the University of Pennsylvania
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP